Literature DB >> 26467022

microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma.

Wei-Hua Song1, Xiao-Jun Feng2, Shao-Juan Gong1, Jian-Ming Chen1, Shou-Mei Wang1,2, Dong-Juan Xing1, Ming-Hua Zhu3, Shu-Hui Zhang2, Ai-Min Xu1.   

Abstract

microRNAs (miRNAs) are important regulators of tumor development and progression. In this study, we aimed to explore the expression and role of miR-622 in hepatocellular carcinoma (HCC). We found that miR-622 was significantly downregulated in human HCC specimens compared to adjacent noncancerous liver tissues. miR-622 downregulation was significantly associated with aggressive parameters and poor prognosis in HCC. Enforced expression of miR-622 significantly decreased the proliferation and colony formation and induced apoptosis of HCC cells. In vivo studies demonstrated that miR-622 overexpression retarded the growth of HCC xenograft tumors. Bioinformatic analysis and luciferase reporter assays revealed that miR-622 directly targeted the 3'-untranslated region (UTR) of mitogen-activated protein 4 kinase 4 (MAP4K4) mRNA. Ectopic expression of miR-622 led to a significant reduction of MAP4K4 expression in HCC cells and xenograft tumors. Overexpression of MAP4K4 partially restored cell proliferation and colony formation and reversed the induction of apoptosis in miR-622-overexpressing HCC cells. Inhibition of JNK and NF-κB signaling phenocopied the anticancer effects of miR-622 on HCC cells. Taken together, miR-622 acts as a tumor suppressor in HCC and restoration of miR-622 may provide therapeutic benefits in the treatment of HCC.

Entities:  

Keywords:  MAP4K4; hepatocellular carcinoma; miR-622; microRNA; therapeutic target

Mesh:

Substances:

Year:  2015        PMID: 26467022      PMCID: PMC4847826          DOI: 10.1080/15384047.2015.1095402

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  28 in total

1.  miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4.

Authors:  Gang Zhao; Bo Wang; Yang Liu; Jun-Gang Zhang; Shi-Chang Deng; Qi Qin; Kui Tian; Xiang Li; Shuai Zhu; Yi Niu; Qiong Gong; Chun-You Wang
Journal:  Mol Cancer Ther       Date:  2013-09-06       Impact factor: 6.261

2.  Expression and prognostic significance of MAP4K4 in lung adenocarcinoma.

Authors:  Mei-Hua Qiu; Yi-Ming Qian; Xiang-Li Zhao; Shou-Mei Wang; Xiao-Jun Feng; Xin-Fang Chen; Shu-Hui Zhang
Journal:  Pathol Res Pract       Date:  2012-07-21       Impact factor: 3.250

Review 3.  MicroRNAs in the p53 network: micromanagement of tumour suppression.

Authors:  Heiko Hermeking
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

4.  Therapeutic Opportunities for Targeting microRNAs in Cancer.

Authors:  Molly A Taylor; William P Schiemann
Journal:  Mol Cell Ther       Date:  2014

5.  Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Authors:  John J Liang; Hua Wang; Asif Rashid; Tse-Hua Tan; Rosa F Hwang; Stanley R Hamilton; James L Abbruzzese; Douglas B Evans; Huamin Wang
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  A functional assay for microRNA target identification and validation.

Authors:  Joop Gäken; Azim M Mohamedali; Jie Jiang; Farooq Malik; Doris Stangl; Alexander E Smith; Constantinos Chronis; Austin G Kulasekararaj; N Shaun B Thomas; Farzin Farzaneh; Mahvash Tavassoli; Ghulam J Mufti
Journal:  Nucleic Acids Res       Date:  2012-02-09       Impact factor: 16.971

7.  MicroRNA-377 suppresses cell proliferation and invasion by inhibiting TIAM1 expression in hepatocellular carcinoma.

Authors:  Guolin Chen; Lu Lu; Chang Liu; Lei Shan; Di Yuan
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

8.  microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.

Authors:  Zheng Zhang; Yang Zhang; Xiu-Xuan Sun; Xi Ma; Zhi-Nan Chen
Journal:  Mol Cancer       Date:  2015-01-21       Impact factor: 27.401

9.  Hepatocellular carcinoma: natural history, current management, and emerging tools.

Authors:  Christopher L Tinkle; Daphne Haas-Kogan
Journal:  Biologics       Date:  2012-07-17

10.  Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.

Authors:  Yonggang Wang; Felix H Shek; Kwong F Wong; Ling Xiao Liu; Xiao Qian Zhang; Yi Yuan; Ester Khin; Mei-Yu Hu; Jian Hua Wang; Ronnie T P Poon; Wanjin Hong; Nikki P Lee; John M Luk
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more
  16 in total

1.  Construction of AP003469.4-miRNAs-mRNAs ceRNA network to reveal potential biomarkers for hepatocellular carcinoma.

Authors:  Tengyang Fan; Guojun Jiang; Rongshu Shi; Ronghua Yu; Xue Xiao; Di Ke
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  Role of microRNAs in inflammation-associated liver cancer.

Authors:  Lin Huan; Lin-Hui Liang; Xiang-Huo He
Journal:  Cancer Biol Med       Date:  2016-12       Impact factor: 4.248

3.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14

Review 4.  Protein-Coding Genes' Retrocopies and Their Functions.

Authors:  Magdalena Regina Kubiak; Izabela Makałowska
Journal:  Viruses       Date:  2017-04-13       Impact factor: 5.048

5.  Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells.

Authors:  Yong Wang; Jie Sun; Xilin Wei; Lan Luan; Xiandong Zeng; Cuifang Wang; Wei Zhao
Journal:  Onco Targets Ther       Date:  2017-02-22       Impact factor: 4.147

6.  The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway.

Authors:  Tian Li; Xiangzhou Sun; Kewei Xu
Journal:  Cell Biosci       Date:  2018-03-02       Impact factor: 7.133

7.  Hsa_circ_0101432 promotes the development of hepatocellular carcinoma (HCC) by adsorbing miR-1258 and miR-622.

Authors:  Haibo Zou; Xiangang Xu; Lanyun Luo; Yu Zhang; Le Luo; Yutong Yao; Guangming Xiang; Xiaolun Huang; Guan Wang
Journal:  Cell Cycle       Date:  2019-07-01       Impact factor: 4.534

Review 8.  Current Status of Gene Therapy in Hepatocellular Carcinoma.

Authors:  Saranya Chidambaranathan Reghupaty; Devanand Sarkar
Journal:  Cancers (Basel)       Date:  2019-08-28       Impact factor: 6.639

9.  Low microRNA-622 expression predicts poor prognosis and is associated with ZEB2 in glioma.

Authors:  Qian Song; Honggang Pang; Lei Qi; Chen Liang; Tuo Wang; Wei Wang; Ruichun Li
Journal:  Onco Targets Ther       Date:  2019-09-10       Impact factor: 4.147

Review 10.  Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma.

Authors:  Lisa Linck-Paulus; Claus Hellerbrand; Anja K Bosserhoff; Peter Dietrich
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.